Immunotherapy for hepatocellular carcinoma

Area of Science:

• Oncology
• Immunology
• Hepatology

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health burden, with rising incidence and mortality rates, making it the third leading cause of cancer death.
• Immune checkpoint inhibitors (ICIs) have revolutionized advanced HCC treatment, offering superior survival benefits over traditional therapies like sorafenib.
• Current standard of care for advanced HCC includes combination therapies such as atezolizumab with bevacizumab or durvalumab with tremelimumab.

Purpose of the Study:

• To review the current understanding of the immune landscape in HCC development.
• To summarize the evidence supporting ICI-based therapeutic strategies in HCC across different disease stages.
• To describe the progress in biomarker development and novel immunotherapy approaches for HCC.

Main Methods:

• Literature review of clinical trials and research studies on HCC and immunotherapy.
• Analysis of the immune microenvironment in HCC.
• Evaluation of biomarker research and early-phase clinical trials for novel immunotherapies.

Main Results:

• ICI-based combination therapies are now standard for advanced HCC and show promise in early/intermediate settings.
• Despite treatment advances, validated predictive biomarkers for ICI response in HCC are still lacking.
• Ongoing research focuses on understanding the HCC tumor microenvironment to identify predictive biomarkers and therapeutic targets.

Conclusions:

• ICI-based therapies represent a significant advancement in HCC treatment, improving survival and progression-free survival.
• The absence of validated predictive biomarkers remains a critical challenge in optimizing ICI therapy for HCC.
• Future research directions include characterizing the tumor immune microenvironment and developing novel immunotherapeutic strategies for HCC.